Seok Joon Yoon1, Sang-Yeon Suh2,3, Yong Joo Lee4, Jeanno Park5, Sunwook Hwang6, Sanghee Shiny Lee7, Hong Yup Ahn7, Su-Jin Koh8, Keon Uk Park9. 1. 1 Department of Family Medicine, Chungnam National University Hospital , Daejeon, South Korea . 2. 2 Department of Medicine, Dongguk University-Seoul , Seoul, South Korea . 3. 3 Department of Family Medicine, Dongguk University Ilsan Hospital , Goyang-si, South Korea . 4. 4 Department of Palliative Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea , Seoul, South Korea . 5. 5 Palliative Care and Hospice Center , Bobath Memorial Hospital, Sungnam, South Korea . 6. 6 Department of Family Medicine, St. Paul's Hospital, College of Medicine, The Catholic University of Korea , Seoul, South Korea . 7. 7 Department of Statistics, Dongguk University-Seoul , Seoul, South Korea . 8. 8 Department of Hemato-oncology, Ulsan University Hospital, University of Ulsan College of Medicine , Ulsan, South Korea . 9. 9 Department of Hemato-oncology, Keimyung University Dongsan Hospital , Daegu, South Korea .
Abstract
BACKGROUND: Objective Prognostic Score (OPS) was developed as an easy and simple prognosticating tool in South Korea. It has been validated retrospectively in a single center in South Korea. OBJECTIVE: We aimed to validate the OPS prospectively for advanced cancer inpatients in South Korea using a multicenter study. DESIGN: This was a prospective cohort study. SETTING/ SUBJECTS: We enrolled 243 advanced cancer patients admitted in five palliative care units in South Korea from May 2013 till March 2015. Seven members of the Korean Palliative Medicine Research Network who are experts of palliative care led the study. MEASUREMENTS: Clinical variables (dyspnea/anorexia/performance status) and laboratory variables (total leukocyte counts/serum total bilirubin/serum creatinine/lactate dehydrogenase) were collected at the enrollment. Survival time was calculated as days from enrollment to death during admission. RESULTS: A total of 217 patients were included in the final analysis (feasibility: 89.3%). Survival time of the higher OPS group (OPS ≥3) and the lower OPS group (OPS <3) was 10.0 (95% confidence interval (CI) 7.72-12.28) days and 32.0 (95% CI 25.44-38.56) days, respectively. There were significant differences between the 2 groups (p < 0.001). Overall accuracy of OPS ≥3 for predicting survival less than three weeks was 71.0%. CONCLUSIONS: OPS was successfully validated using a prospective multicenter study in South Korea. It is a useful method to predict three-week survival of Korean inpatients with advanced cancer.
BACKGROUND: Objective Prognostic Score (OPS) was developed as an easy and simple prognosticating tool in South Korea. It has been validated retrospectively in a single center in South Korea. OBJECTIVE: We aimed to validate the OPS prospectively for advanced cancer inpatients in South Korea using a multicenter study. DESIGN: This was a prospective cohort study. SETTING/ SUBJECTS: We enrolled 243 advanced cancerpatients admitted in five palliative care units in South Korea from May 2013 till March 2015. Seven members of the Korean Palliative Medicine Research Network who are experts of palliative care led the study. MEASUREMENTS: Clinical variables (dyspnea/anorexia/performance status) and laboratory variables (total leukocyte counts/serum total bilirubin/serum creatinine/lactate dehydrogenase) were collected at the enrollment. Survival time was calculated as days from enrollment to death during admission. RESULTS: A total of 217 patients were included in the final analysis (feasibility: 89.3%). Survival time of the higher OPS group (OPS ≥3) and the lower OPS group (OPS <3) was 10.0 (95% confidence interval (CI) 7.72-12.28) days and 32.0 (95% CI 25.44-38.56) days, respectively. There were significant differences between the 2 groups (p < 0.001). Overall accuracy of OPS ≥3 for predicting survival less than three weeks was 71.0%. CONCLUSIONS: OPS was successfully validated using a prospective multicenter study in South Korea. It is a useful method to predict three-week survival of Korean inpatients with advanced cancer.